Droloxifene

Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats [1][2][3].

Product Specifications

CAS Number

[82413-20-5]

Product Name Alternative

3-Hydroxytamoxifen

UNSPSC

12352005

Hazard Statement

H317, H351, H360, H410

Target

Apoptosis; Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Apoptosis; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/droloxifene.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC1=CC=CC(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CC)=C1

Molecular Formula

C26H29NO2

Molecular Weight

387.51

Precautions

H317, H351, H360, H410

References & Citations

[1]Herrington DM, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthypostmenopausal women. Arterioscler Thromb Vasc Biol. 2000 Jun;20 (6) :1606-12.|[2]Grasser WA, et al. Common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cell Biochem. 1997 May;65 (2) :159-71.|[3]Ke HZ, et al. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. ndocrinology. 1995 Jun;136 (6) :2435-41.|[4]Huang Y, et al. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta Pharmacol Sin. 2005 Oct;26 (10) :1243-7.